Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 182 | 134 | 48 |
| Samples | 175 | 127 | 48 |
| Peptides | 81 | 52 | 40 |
Function
MT-ND6 · NADH dehydrogenase subunit 6
Enables NADH dehydrogenase (ubiquinone) activity. Involved in mitochondrial electron transport, NADH to ubiquinone and mitochondrial respiratory chain complex I assembly. Predicted to be located in mitochondrial inner membrane. Implicated in Leber hereditary optic neuropathy; Leigh disease; and spinal muscular atrophy with lower extremity predominante 2B. [provided by Alliance of Genome Resources, Apr 2022]
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000361681 | P03923 | 182 | 81 |
Gene Properties
Recurrent Mutations
All 81 amino-acid changes on canonical ENST00000361681 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in MT-ND6 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in MT-ND6 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| Acute Myeloid Leukemia | 3/90 3% | 0/0 0% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Hodgkins Lymphoma | 2/16 12% | 0/122 0% |
| Endometrial Carcinoma | 0/42 0% | 8/612 1% |
| Chondrosarcoma | 1/14 7% | 0/75 0% |
| Rhabdomyosarcoma | 2/33 6% | 0/171 0% |
| Ewings Sarcoma | 3/63 5% | 0/262 0% |
| Biliary Tract Carcinoma | 5/54 9% | 4/950 0% |
| Plasma Cell Myeloma | 3/44 7% | 0/305 0% |
| Meningioma | 0/3 0% | 2/252 1% |
| Non-Small Cell Lung Carcinoma | 11/304 4% | 2/1390 0% |
| Other Solid Cancers | 10/94 11% | 2/1515 0% |
| Kidney Carcinoma | 2/85 2% | 12/1862 1% |
| Non-Cancerous | 5/104 5% | 1/830 0% |
| Neuroendocrine Tumour | 4/154 3% | 0/577 0% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Breast Carcinoma | 11/144 8% | 5/3264 0% |
| Squamous Cell Lung Carcinoma | 4/57 7% | 0/810 0% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Neuroblastoma | 6/87 7% | 0/1331 0% |
| Esophageal Carcinoma | 1/23 4% | 2/769 0% |
| Gastric Carcinoma | 7/74 9% | 0/1809 0% |
| Pancreatic Carcinoma | 5/89 6% | 0/1611 0% |
| Melanoma | 5/210 2% | 1/1899 0% |
| Ovarian Carcinoma | 2/109 2% | 1/998 0% |
| Colorectal Carcinoma | 1/143 1% | 7/3239 0% |
| B-Cell Non-Hodgkins Lymphoma | 5/88 6% | 1/2534 0% |
| Cervical Carcinoma | 1/35 3% | 0/422 0% |
Mutation Distribution
Where MT-ND6 is mutated · all tissues, split by cell line vs tissue
How many mutations in MT-ND6 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 182 mutations in MT-ND6
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|